Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
BPC-157 has been called a miracle, a scam, a research peptide, a recovery hack, and, briefly, a banned substance. In April 2026 the FDA pulled it off the Category 2 list it had been parked on since 2023, and in July an FDA advisory committee voted to recommend it for the legal compounding list. None of that resolves the actual question wellness consumers keep asking: does this thing work, and is it safe to put in your body?
Short answer: the mechanism is coherent, the animal data is extensive, the human data is thin enough that you can see through it, and the regulatory picture has moved four times since 2023 without ever making the peptide legal to buy. Here's the honest read.
BPC-157 stands for Body Protection Compound-157. It's a synthetic 15-amino-acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) [1], modeled on a fragment of a larger protective protein that sits in human gastric juice [2].
The "protective" part isn't marketing.
Croatian researchers - who did most of the foundational work starting in the 1990s [3] - isolated the parent protein for a simple reason: stomach lining is one of the most regenerative tissues anywhere in the body, and they wanted to figure out why.
That origin matters for one practical reason. BPC-157 is unusually stable in stomach acid - most peptides get torn apart on contact - which is why oral formulations are even on the table. Most injectable peptides don't have that option.
It's also worth being clear about what BPC-157 isn't. Not a hormone. Not anabolic the way testosterone is anabolic, and not a stimulant either. And as of mid-2026, it's not an FDA-approved drug for any indication, anywhere on the planet.
The mechanism story has gotten cleaner in the last few years, which is part of why the peptide keeps getting taken seriously by people who would otherwise dismiss it.
Two pathways, both ending at nitric oxide. The first goes through VEGFR2 - the receptor for vascular endothelial growth factor - and runs the classic PI3K/Akt/eNOS cascade that endothelial cells use to build new blood vessels [4]. The second is VEGF-independent: it activates Src kinase, which phosphorylates caveolin-1, which then activates eNOS by a different route [5]. The redundancy is the point. Damaged tissue often has impaired VEGF signaling. BPC-157 appears to route around that.
Downstream, the effect is angiogenesis - new capillaries growing into injured tissue, bringing oxygen and clearing debris. That's the proposed engine behind almost every reported benefit, from tendon repair to gut healing.
There's more, and this is where the mechanism literature starts feeling busy. BPC-157 upregulates cytoprotective proteins like heme oxygenase-1 and heat shock proteins [6]. It appears to stabilize mitochondria under oxidative stress. It modulates glutamate signaling in ways that look neuroprotective in rodent models. It pushes fibroblasts toward collagen synthesis. In isolated rat aorta it produces dose-dependent vasodilation that disappears when you block nitric oxide synthesis [7], which is about as cleanly as a mechanism can be showed in a tissue prep.
Pharmacokinetically, it's fast. Plasma half-life under 30 minutes in rats and dogs [8]. Peak concentrations within minutes of intramuscular injection. Back to baseline within a day. Bioavailability after IM injection runs roughly 14-19% in rats and 45-51% in dogs [9] - a species gap that the human data hasn't yet filled in.
Here's where the honest reader has to slow down.
The animal evidence is broad and surprisingly consistent. Across rodent and rabbit models, BPC-157 speeds tendon and ligament healing, closes gastric ulcers, and improves muscle regeneration after crush injury. It also blunts Parkinson's-like and Alzheimer's-like pathology in induced models. And here's the odd part: given its angiogenic activity, you'd expect it to feed tumors. In several induced cancer models, it appears to do the opposite.
The mechanistic story holds up across labs and endpoints.
The human evidence doesn't match this picture.
Three small uncontrolled pilot studies. One Phase I safety trial whose results stayed unpublished a decade after it got registered. One Phase II trial just now starting to recruit. That's it.
The three published human studies share a few problems. Same primary investigator (Eric Lee), same complementary-medicine journal (Alternative Therapies in Health and Medicine) [10], and in every case the clinics running the work had a commercial stake in how things turned out. The studies report no adverse events and meaningful symptom improvement in patients with knee pain, interstitial cystitis (a small intravesical-injection pilot), and intravenous safety endpoints. No control group. No blinding. The interstitial cystitis pilot, in particular, involves a procedure - injecting something into the bladder wall - that carries its own placebo and procedural effects quite apart from whatever's actually in the syringe.
That's not a literature. That's a sketch.
The Phase I trial (NCT02637284) [11] tested oral BPC-157 tablets in healthy volunteers. By the limited reporting available, it was well tolerated, with no clinically meaningful changes in vitals, ECG, or labs. The results have not been formally published. That trial was registered in December 2015. That's eleven years of silence.
A Phase II randomized, double-blind, placebo-controlled trial for acute Grade II hamstring strain (NCT07437547, sponsored by Hudson Biotech) [12] registered in February 2026 and is currently recruiting. It will, if completed and published, be the first methodologically serious human efficacy data on BPC-157 anywhere.
A 2025 peer-reviewed narrative review put it bluntly: until well-designed human trials are conducted and published, BPC-157 shouldn't be recommended for clinical use in musculoskeletal medicine [13]. That's the current state of the literature, stated plainly.
Strip away the marketing and the reported use cases cluster into a few buckets:
Tendon and ligament injury. This is the dominant use among athletes and the rehab-curious. The rationale traces directly to the rodent tendon-healing literature. Whether it works in humans the way it works in rats is the question the Phase II trial is finally going to test.
Gut health. Inflammatory bowel symptoms, leaky gut, gastritis, post-NSAID damage. Oral BPC-157 makes the most sense pharmacologically here, because the peptide is acid-stable and the tissue you're targeting is directly exposed to it.
Post-surgical recovery and general inflammation. This is where the use cases get fuzziest. The mechanism is plausible. The evidence is not.
Neuroprotection and mood. A smaller cluster, drawing from rodent models of TBI, Parkinson's, and depression-like behavior. Almost no human data.
Reports of widespread BPC-157 use through 503A compounding pharmacies in the years before the FDA acted are common in the trade press but lack any rigorous, source-able denominator. What's clear is that use was widespread; what isn't clear is what the actual safety profile of that use was.
Three formats dominate, and they're not interchangeable.
Subcutaneous injection is the most common for systemic and musculoskeletal use. Higher bioavailability than oral, faster onset, dose-flexible. Most underground protocols cited online land somewhere in the 200-500 mcg/day range, though "online protocol" is doing a lot of unscientific lifting in that sentence.
Oral capsules or tablets are the format used in the Phase I trial and the format that makes pharmacological sense for gut-localized conditions. Systemic exposure is lower; local exposure to GI tissue is high. The acid stability is real.
Intramuscular injection has been characterized in animal PK studies but isn't a typical patient-facing route. Intra-articular and intravesical injection have been used in the small pilot studies but require a clinician and aren't relevant for consumer self-administration.
The half-life under 30 minutes raises a real question that the literature hasn't answered: if plasma levels crash within an hour, how does any sustained therapeutic effect actually accumulate? One hypothesis is that the angiogenic and growth-factor signals get triggered fast and the tissue effect outlasts the molecule. Another is that frequent dosing matters more than total dose. Nobody has tested this rigorously in people.
The short-term human safety picture, from what little we have, looks reassuring. The Phase I trial saw no signal. The pilot studies, despite their methodological weakness, reported no adverse events. Compounding-pharmacy anecdote points the same direction.
What FAERS-style postmarketing data exist for an unapproved peptide are difficult to interpret. Voluntary, uncontrolled adverse-event reporting can include almost anything about the patient's history, and BPC-157 has no FDA approval against which to anchor a denominator. Worth flagging: BPC-157 is rapidly cleared via the kidneys and biliary tract, and some clinicians have reported caution in patients with pre-existing renal or hepatic disease.
Then there's the oncology question, which is genuinely unresolved.
BPC-157 upregulates VEGFR2, eNOS, and EGR-1 [14]. Those are the same pathways tumors use to build their own blood supply. On paper, this should worry you. In practice, the preclinical evidence so far points the other direction - BPC-157 has actually inhibited tumor proliferation in induced cancer models, possibly because its effect on angiogenesis is regulated rather than runaway. That's the current best read.
What doesn't exist: long-term human data. Nobody has tracked a cohort of BPC-157 users for five or ten years to see what shakes out. Until someone does, the honest answer to "is it safe to use for a year?" is that we don't know.
A separate risk is contamination. Gray-market BPC-157 sold "for research purposes only" comes from sources with no obligation to meet pharmaceutical purity standards. Endotoxin contamination, incorrect dosing, and microbial impurities are real and have nothing to do with the peptide itself.
Late 2023: the FDA placed BPC-157 on its Category 2 bulk drug substances list, effectively prohibiting 503A compounding pharmacies from preparing it, citing unspecified "real safety risks." The peptide didn't disappear - gray-market sales continued under "research use only" labeling, which the FDA itself described as a whack-a-mole enforcement problem.
February 2026: HHS Secretary Robert F. Kennedy Jr. Publicly addressed the Category 2 status [15]. The companies that had nominated peptides for compounding pulled their nominations.
April 2026: BPC-157 came off Category 2 [16]. Compounding restrictions were partly lifted, pending further FDA review.
July 23–24, 2026: the FDA's Pharmacy Compounding Advisory Committee met and voted to recommend BPC-157 for the 503A bulks list — 8 in favour, 6 against, 1 abstention, with the free base and the acetate salt voted separately and coming back the same way each time [17]. The vote went against the agency's own reviewers, who had proposed rejecting it on the grounds that there was no evidence of effectiveness and insufficient clinical safety information. Our report on the meeting has the full record.
That's where things stand, and the July vote changed less than it sounds like. A committee recommendation is non-binding. FDA has issued no final determination, and BPC-157 is not on the 503A positive list — it still has no USP monograph and isn't a component of any approved drug [18]. To be legally compoundable a substance generally needs to meet one of those criteria, and BPC-157 meets none. Adding a substance to the list happens through rulemaking: a proposed rule in the Federal Register, a comment period, then a final rule. None of that has started, and there is no published timeline.
So the honest current status is the same as it was in April, just better documented: not prohibited, not authorised.
For consumers, the practical effect goes like this: BPC-157 sits in a more permissive regulatory zone than it did a year ago, but it's still an unapproved drug, and online sale "for research" to people who plan to use it therapeutically remains, under current FDA reading, distribution of an unapproved new drug.
BPC-157 is one of the more biologically interesting peptides in the compounded landscape right now. The mechanism story holds together. Animal evidence is real, and the short-term human safety signal - for what limited data exists - hasn't raised alarms.
It's also a compound that has been used widely on the basis of essentially zero rigorous human efficacy data. The first proper randomized trial is recruiting now, eleven years after the Phase I trial that still hasn't been published.
The honest read: BPC-157 is neither the miracle nor the scam. It's an investigational peptide with a plausible mechanism, encouraging preclinical data, a thin and conflicted human literature, an unresolved long-term safety profile, and a regulatory status that's likely to be clarified - in one direction or another - at the FDA's July meeting. People who use it now are doing so without the support of randomized clinical evidence in humans.
BPC-157 doesn't fit the profile of a peptide with a settled evidence base and a clear regulatory home. Anyone considering it would be better served by a licensed clinician who can monitor labs and outcomes than by a research-peptide vendor operating without oversight. BPC-157 is often stacked with TB-500 for recovery; for a structured side-by-side, see our BPC-157 vs TB-500 comparison.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide modeled on a fragment of a protective protein found in human gastric juice. It's unusually acid-stable, which is why oral forms exist, but it's not FDA-approved anywhere.
The animal evidence for tendon, gut, and muscle healing is broad and consistent, but the human evidence is very thin — a few small uncontrolled pilots and an unpublished Phase I. The first proper randomized human trial only began recruiting in 2026.
Short-term human and animal data haven't raised alarms, but there's no long-term human safety data. The theoretical oncology concern (it acts on VEGF pathways) is so far unsupported — in animal models it has inhibited, not fed, tumors. Gray-market contamination is a separate, real risk.
Most commonly by subcutaneous injection for systemic or musculoskeletal use, or oral capsules for gut conditions where acid stability helps. Online protocols cluster around 200–500 mcg/day, but those doses aren't clinically validated.
It's not FDA-approved and not on the 503A positive list. It came off the Category 2 list in April 2026, and in July 2026 an FDA advisory committee voted 8–6–1 to recommend adding it to the list — but neither of those is approval, and the recommendation is non-binding until FDA acts on it. Selling it "for research" to people who plan to use it remains distribution of an unapproved new drug.
Editorial note: Informational only — not medical advice. Decisions about peptide therapy should be made with a licensed healthcare provider familiar with your medical history. See our methodology. Last reviewed July 2026.